SG11201702813VA - Pharmaceutical formulations for the oral delivery of peptide or protein drugs - Google Patents

Pharmaceutical formulations for the oral delivery of peptide or protein drugs

Info

Publication number
SG11201702813VA
SG11201702813VA SG11201702813VA SG11201702813VA SG11201702813VA SG 11201702813V A SG11201702813V A SG 11201702813VA SG 11201702813V A SG11201702813V A SG 11201702813VA SG 11201702813V A SG11201702813V A SG 11201702813VA SG 11201702813V A SG11201702813V A SG 11201702813VA
Authority
SG
Singapore
Prior art keywords
peptide
pharmaceutical formulations
oral delivery
protein drugs
drugs
Prior art date
Application number
SG11201702813VA
Inventor
Florian Föger
Original Assignee
Cyprumed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51751911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201702813V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cyprumed Gmbh filed Critical Cyprumed Gmbh
Publication of SG11201702813VA publication Critical patent/SG11201702813VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG11201702813VA 2014-10-07 2015-10-07 Pharmaceutical formulations for the oral delivery of peptide or protein drugs SG11201702813VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14187885.0A EP3006045B3 (en) 2014-10-07 2014-10-07 Pharmaceutical formulations for the oral delivery of peptide or protein drugs
PCT/EP2015/073196 WO2016055550A1 (en) 2014-10-07 2015-10-07 Pharmaceutical formulations for the oral delivery of peptide or protein drugs

Publications (1)

Publication Number Publication Date
SG11201702813VA true SG11201702813VA (en) 2017-05-30

Family

ID=51751911

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702813VA SG11201702813VA (en) 2014-10-07 2015-10-07 Pharmaceutical formulations for the oral delivery of peptide or protein drugs

Country Status (16)

Country Link
US (1) US20170304195A1 (en)
EP (2) EP3006045B3 (en)
JP (1) JP2017531665A (en)
KR (1) KR20170061140A (en)
CN (1) CN106794252A (en)
AU (1) AU2015330016A1 (en)
BR (1) BR112017006957A2 (en)
CA (1) CA2960334A1 (en)
DK (1) DK3006045T3 (en)
ES (1) ES2630106T3 (en)
IL (1) IL251462A0 (en)
MX (1) MX2017004592A (en)
RU (1) RU2017115651A (en)
SG (1) SG11201702813VA (en)
WO (1) WO2016055550A1 (en)
ZA (1) ZA201701719B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
JP2018529749A (en) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー Pharmaceutical formulations for oral delivery of peptide drugs
ES2904891T3 (en) * 2016-04-18 2022-04-06 Radius Health Inc Abaloparatide formulations, transdermal patch thereof and uses thereof
CN109803639B (en) * 2016-09-29 2024-01-02 艾瑞克有限公司 New formulation
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
SG10201609137PA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Gamma-polyglutamic acid and zinc compositions
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
CN109381695A (en) * 2017-08-09 2019-02-26 武汉武药科技有限公司 A kind of L-aminobutanedioic acid parritide injection and its preparation method and application
TWI751379B (en) * 2017-09-21 2022-01-01 奧孟亞股份有限公司 Pharmaceutical composition for delivery of peptide
WO2019078663A2 (en) * 2017-10-20 2019-04-25 주식회사 노브메타파마 Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients
CN108079280B (en) * 2017-12-30 2021-06-04 陕西慧康生物科技有限责任公司 Exenatide nasal drops for treating type II diabetes
TWI829687B (en) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN108721598B (en) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 Preparation method of oxytocin raw material, pharmaceutical composition and preparation thereof
BR112021008602A2 (en) 2018-11-26 2021-08-03 The Procter & Gamble Company solid pharmaceutical preparation containing lipoic acid and its use
CN110251662B (en) * 2018-12-12 2023-01-31 福州市台江区希吉亚健康科技有限公司 A medicine with weight reducing effect
CN110251661B (en) * 2018-12-12 2022-09-16 福州市台江区希吉亚健康科技有限公司 A medicinal preparation for treating diabetes or reducing weight
WO2020130649A1 (en) * 2018-12-19 2020-06-25 대화제약 주식회사 Oral pharmaceutical composition comprising glp-1 analogue
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
CN112138148B (en) * 2019-06-10 2024-04-09 苏州兰鼎生物制药有限公司 Oral pharmaceutical composition of growth hormone or analogue thereof
CN112057619A (en) * 2019-06-10 2020-12-11 苏州兰鼎生物制药有限公司 A pharmaceutical composition with blood sugar lowering effect
WO2020257260A1 (en) 2019-06-17 2020-12-24 Massachusetts Institute Of Technology Formulation of peptide loaded liposomes and related applications
EP4017278A4 (en) * 2019-08-21 2023-09-13 Brain Chemistry Labs Compositions comprising a metal and l-serine, and uses thereof
KR102216578B1 (en) * 2019-09-05 2021-02-17 주식회사 아이큐어비앤피 Oral pharmaceutical composition comprising teriparatide and method for preparing the same
JP2022548221A (en) * 2019-09-09 2022-11-17 テジュン ファーマシューティカル カンパニー リミテッド Nanoemulsion ophthalmic composition containing cyclosporine and menthol and method for producing the same
CN112972656B (en) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 Oral pharmaceutical composition of glucagon-like peptide-2 or analogues thereof
CN112972692A (en) * 2019-12-14 2021-06-18 苏州兰鼎生物制药有限公司 Pharmaceutical composition for promoting intestinal absorption
CN113509544B (en) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 Pharmaceutical composition with blood sugar reducing effect
CN112972650B (en) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 Oral pharmaceutical composition of somatostatin or analogue thereof
CN112972659A (en) * 2019-12-14 2021-06-18 苏州兰鼎生物制药有限公司 Oral pharmaceutical composition of teriparatide or abamectin
CN112972658B (en) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 Oral pharmaceutical composition of growth hormone or analogue thereof
CN113171446B (en) * 2021-05-06 2022-03-29 合肥天汇孵化科技有限公司 Liraglutide compositions and uses thereof
EP4226918A1 (en) * 2022-02-15 2023-08-16 Filip Majewski Pharmaceutical single dosage form for oral delivery of peptides
KR102492241B1 (en) * 2022-02-25 2023-01-30 전남대학교산학협력단 Peptide interfering a dimerization of KITENIN and use thereof
TW202400219A (en) * 2022-04-29 2024-01-01 香港商鵬躍醫藥科技有限公司 A pharmaceutical compositions of semaglutide and the salts for intranasal administration
CN115161253B (en) * 2022-05-30 2022-12-02 微康益生菌(苏州)股份有限公司 Probiotic inactivation method for keeping cell structural integrity and application thereof
EP4299071A1 (en) * 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
CN114984191B (en) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 Oral delivery composition of polypeptide drugs
WO2024077409A1 (en) * 2022-10-09 2024-04-18 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
CN118001411A (en) * 2024-04-09 2024-05-10 深圳奥礼生物科技有限公司 Intestinal tract absorption composition

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (en) 1992-03-25 1992-03-25 Bernard Thorens PEPTIDE
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
PT944648E (en) 1996-08-30 2007-06-26 Novo Nordisk As Glp-1 derivatives
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2002504518A (en) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ GLP-1 derivatives with helix-content of more than 25% forming partially structured micellar-like aggregates
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
DE69942306D1 (en) 1998-02-27 2010-06-10 Novo Nordisk As ABSTRACT OF GLP-1 ANALOG
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
CA2369591C (en) 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
WO2001072312A1 (en) * 1999-12-22 2001-10-04 Viron Corporation Antiviral therapeutic composition and treatment
US20010012829A1 (en) * 2000-01-11 2001-08-09 Keith Anderson Transepithelial delivery GLP-1 derivatives
WO2003007913A2 (en) 2001-07-20 2003-01-30 Samir Mitragotri Method for oral drug delivery
AU2004273573B2 (en) 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
RU2006135552A (en) * 2003-11-19 2008-04-20 Веста Лтд. (Il) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO HELIKOBAKTER PYROLI. USING COMPOUNDS CONTAINING AN ENDOPEROXIDE BRIDGE
EP1704165B1 (en) 2003-12-18 2010-03-17 Novo Nordisk A/S Glp-1 compounds
JP2007537142A (en) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ Novel GLP-1 analogues bound to albumin-like substances
WO2005113592A2 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CN101005857A (en) 2004-07-08 2007-07-25 诺和诺德公司 Polypeptide protracting tags
JP2006028031A (en) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd Medicine-sealed nano particle for transmucosa absorption
NZ553263A (en) 2004-07-19 2010-06-25 Biocon Ltd Insulin-oligomer conjugates, formulations and uses thereof
WO2006124047A2 (en) * 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP5066448B2 (en) * 2004-09-03 2012-11-07 協和発酵バイオ株式会社 Compositions and methods for the prevention or treatment of stomatitis
EP1799710A2 (en) 2004-10-07 2007-06-27 Novo Nordisk A/S Protracted glp-1 compounds
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
US20090123563A1 (en) 2005-02-07 2009-05-14 Novo Nordisk A/S Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand
JP5755398B2 (en) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス Elongated GLP-1 compound
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US7618669B2 (en) * 2005-06-01 2009-11-17 Mead Johnson Nutrition Company Low-lactose partially hydrolyzed infant formula
ES2462117T3 (en) 2005-09-06 2014-05-22 Oramed Pharmaceuticals Inc. Methods and compositions for oral protein administration
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
JP2009517410A (en) * 2005-11-30 2009-04-30 ジェネレクス ファーマシューティカルズ インコーポレイテッド Oral absorbed pharmaceutical preparation and administration method
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
ES2371361T3 (en) 2005-12-28 2011-12-30 Novo Nordisk A/S COMPOSITIONS THAT INCLUDE AN INSULIN ACILADA AND ZINC AND METHOD OF PRODUCTION OF SUCH COMPOSITIONS.
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
JP5476304B2 (en) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
TWI394580B (en) 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions
WO2010019266A2 (en) * 2008-08-15 2010-02-18 Ironwood Pharmaceuticals, Inc. Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
MX2012001660A (en) * 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Linaclotide-containing formulations for oral administration.
IN2012DN03140A (en) 2009-09-30 2015-09-18 Thiomatrix Forschungs Und Beratungs Gmbh
GB2478849A (en) * 2010-03-16 2011-09-21 Chiasma Inc Improved pharmecutical compositions and methods of delivery
CA2796853A1 (en) 2010-04-21 2011-10-27 Hsing-Wen Sung A pharmaceutical composition of nanoparticles
KR20130092972A (en) 2010-05-10 2013-08-21 노보 노르디스크 에이/에스 Process for the preparation of insulin-zinc complexes
TW201202178A (en) * 2010-06-04 2012-01-16 Chemo Iberica Sa Process for producing Aliskiren
WO2012080471A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP2665469A1 (en) * 2011-01-19 2013-11-27 Novo Nordisk A/S Glp-1 compositions
WO2012112319A1 (en) 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof
JP6030630B2 (en) 2011-04-14 2016-11-24 ノヴォ ノルディスク アー／エス Fatty acylated amino acids for oral peptide delivery
CN103732215B (en) * 2011-06-10 2017-07-11 莫诺索Rx有限责任公司 Combine peptide nanoparticles and mix its delivery system
US20130004590A1 (en) 2011-06-28 2013-01-03 Lin Connie B Zinc oxide/acid containing compositions and methods for treating and/or preventing enzymatic irritation
BR112014005091A2 (en) * 2011-09-05 2017-06-13 Beijing Hanmi Pharmaceutical Co Ltd pharmaceutical composition for the treatment of cancer comprising interferon alpha conjugate
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
CA2915358A1 (en) 2012-06-14 2013-12-19 Entrega, Inc. Mucoadhesive devices for delivery of active agents
EP3459598A1 (en) * 2012-12-06 2019-03-27 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same
CN103948915B (en) * 2014-05-05 2016-06-22 德立唯（北京）生物科技有限公司 A kind of natto kinase composition for antithrombotic and thrombolytic that can improve stability and oral curative effect
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs

Also Published As

Publication number Publication date
WO2016055550A1 (en) 2016-04-14
KR20170061140A (en) 2017-06-02
DK3006045T3 (en) 2017-07-17
AU2015330016A1 (en) 2017-04-20
CN106794252A (en) 2017-05-31
ES2630106T3 (en) 2017-08-18
EP3006045B3 (en) 2021-03-17
EP3204045A1 (en) 2017-08-16
RU2017115651A (en) 2018-11-20
EP3006045A1 (en) 2016-04-13
MX2017004592A (en) 2017-07-10
EP3006045B1 (en) 2017-04-12
CA2960334A1 (en) 2016-04-14
EP3204045B1 (en) 2018-12-05
JP2017531665A (en) 2017-10-26
IL251462A0 (en) 2017-05-29
BR112017006957A2 (en) 2017-12-19
ZA201701719B (en) 2018-05-30
US20170304195A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
IL251462A0 (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs
IL258464A (en) Pharmaceutical formulations for the oral delivery of peptide drugs
IL275220A (en) Oral delivery of active drug substances
ZA201903101B (en) Pharmaceutical formulations
HUP1700253A1 (en) Solid preparations for oral administration
IL273740A (en) Pharmaceutical oral formulation comprising bacteria
IL262568A (en) Protein based excipient for active pharmaceutical ingredients
ZA201703562B (en) Pharmaceutical composition for oral administration comprising taxane
HK1248544A1 (en) Stable pharmaceutical composition for oral administration
ZA201800470B (en) An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
IL273451A (en) Pharmaceutical compositions for delivery of peptide
HK1245646A1 (en) Pharmaceutical composition for oral administration
PT3650024T (en) Pharmaceutical composition for nasal administration
HK1232144A1 (en) Pharmaceutical composition for oral administration
IL250394A0 (en) Oral composition for delivery of drugs and other substances
IL252080A0 (en) Oral administration of unstable or poorly-absorbed drugs
GB201610440D0 (en) Pharmaceutical formulations